A

Atea Pharmaceuticals
D

AVIR

3.11000
USD
-0.13
(-4.01%)
مغلق
حجم التداول
14,357
الربح لكل سهم
0
العائد الربحي
-
P/E
-2
حجم السوق
262,680,113
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABUS
    0.02000
    (0.63%)
    3.22000 USD
    A
    ADAP
    -0.00560
    (-0.97%)
    0.57280 USD
    A
    ASND
    -4.910
    (-3.75%)
    126.150 USD
    C
    CRNC
    0.940
    (6.87%)
    14.620 USD
    G
    GERN
    0.03500
    (1.18%)
    2.99500 USD
    I
    ICHR
    -0.630
    (-2.06%)
    30.000 USD
    N
    NVAX
    0.02500
    (0.28%)
    8.84500 USD
    X
    XENE
    0.220
    (0.56%)
    39.250 USD
    المزيد
الأخبار
المقالات

العنوان: Atea Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).